How do Attruby and tafamidis compare for treating cardiac amyloidosis?
Both Attruby (acoramidis) and tafamidis are effective TTR stabilizers approved for treating ATTR cardiomyopathy. They work similarly by preventing the TTR protein from breaking apart and forming harmful amyloid deposits in the heart.
Tafamidis has been Show Full Answer
How do Attruby and tafamidis compare for treating cardiac amyloidosis?
Both Attruby (acoramidis) and tafamidis are effective TTR stabilizers approved for treating ATTR cardiomyopathy. They work similarly by preventing the TTR protein from breaking apart and forming harmful amyloid deposits in the heart.
Tafamidis has been available longer, approved in 2019. Long-term studies show it can:
- Improve heart function
- Help people live longer
- Improve stamina and daily activities like walking and exercise
- Reduce mortality risk significantly when started early
Attruby (acoramidis) is newer, approved in 2024. Studies show it can:
- Improve heart function
- Reduce serious heart risks
- Improve how people feel day to day
- Offer the most benefit when treatment starts early
Both medications are taken once daily by mouth and work for hereditary and wild-type ATTR cardiomyopathy.
The key difference is that tafamidis has more long-term data showing sustained benefits over years, while acoramidis is newer with promising early results but less long-term information available yet.
Your cardiologist can help determine which medication might be best for your specific situation based on your heart function, disease progression, and individual needs.
March 26
Join
Your Privacy Choices
